Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Osteosarcoma Clear all
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Pulmonary Metastatic Osteosarcoma (pOS)
Interventions
Natalizumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
5 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced May 21, 2026, 7:20 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Sarcoma, Soft Tissue Sarcoma, Metastatic Sarcoma, Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Leiomyosarcoma, Liposarcoma, Angiosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, Spindle Cell Sarcoma, High Grade Sarcoma, Bone Sarcoma
Interventions
Gemcitabine, Docetaxel, 9-ING-41
Drug
Lead sponsor
Brown University
Other
Eligibility
10 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced May 21, 2026, 7:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Cancer
Interventions
immunological diagnostic method, physiologic testing
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced May 21, 2026, 7:20 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Osteosarcoma, Pulmonary Metastasis, Fluorescence, Metastatic Sarcoma, Pediatrics
Interventions
Cytalux
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Malignant Hemangiopericytoma, Adult Malignant Mesenchymoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Neurofibrosarcoma, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery, 3-dimensional conformal radiation therapy, ifosfamide
Drug · Other · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 133 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Ewing's Sarcoma
Interventions
Olaparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
hu14.18-IL2 fusion protein
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
54
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced May 21, 2026, 7:20 PM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Bone Cancer, Metastasis
Interventions
Guanabenz acetate
Drug
Lead sponsor
Kathy Miller
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Osteosarcoma, Ewing Sarcoma Family Tumors, Malignant Fibrous Histiocytoma, Sarcoma, Synovial, Fibrosarcoma, Leiomyosarcoma
Interventions
REOLYSIN®
Biological
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
16 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced May 21, 2026, 7:20 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
Interventions
ST-01156
Drug
Lead sponsor
SEED Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Duarte, California • Newport Beach, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Sarcoma
Interventions
cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, zoledronic acid, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, filgrastim, Mesna
Drug · Procedure · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
77
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 70 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced May 21, 2026, 7:20 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Osteosarcoma, Metastatic Osteosarcoma
Interventions
pazopanib
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Duarte, California • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced May 21, 2026, 7:20 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Localized Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 39 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Mesenchymoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Childhood Angiosarcoma, Childhood Desmoplastic Small Round Cell Tumor, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Malignant Peripheral Nerve Sheath Tumor, Childhood Pleomorphic Rhabdomyosarcoma, Childhood Rhabdomyosarcoma With Mixed Embryonal and Alveolar Features, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Malignant Adult Hemangiopericytoma, Malignant Childhood Hemangiopericytoma, Metastatic Childhood Soft Tissue Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
Interventions
Cixutumumab, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Osteosarcoma
Interventions
Rexin-G Dose 1, Rexin-G Dose 2
Genetic
Lead sponsor
Epeius Biotechnologies
Industry
Eligibility
10 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced May 21, 2026, 7:20 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma, Recurrent Angiosarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Osteosarcoma, Refractory Dedifferentiated Liposarcoma, Refractory Osteosarcoma
Interventions
Durvalumab, Oleclumab
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Advanced and/or Metastatic Sarcoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced May 21, 2026, 7:20 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
Interventions
Iodine I 131 MOAB 8H9
Drug
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
Not listed
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bone Cancer, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Metastatic Osteosarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Recurrent Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma
Interventions
therapeutic angiotensin-(1-7), laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced May 21, 2026, 7:20 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Ewing Sarcoma
Interventions
Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, Actinomycin, Irinotecan, Cabozantinib, Topotecan, Temozolomide, Etoposide, Liposomal doxorubicin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
1 Year and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hartford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 7:20 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Refractory and/or Relapsed Metastatic Solid Tumors
Interventions
Cyclophosphamide, Fludarabine, low dose total body irradiation, Melphalan, Tacrolimus
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
1 Year to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
3
States / cities
Baltimore, Maryland • The Bronx, New York • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Osteosarcoma
Interventions
pre-surgical chemotherapy
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 21, 2026, 7:20 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Ewing Sarcoma, Rhabdomyosarcoma
Interventions
Olaparib, Temozolomide, Irinotecan
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
5
States / cities
Boston, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced May 21, 2026, 7:20 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic
Interventions
Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
5 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced May 21, 2026, 7:20 PM EDT